Immunovant Inc

XNAS:IMVT

26.42

+1.61 (+6.49%)

7:59:45 PM EDT: $27.13 +0.71 (+2.69%)

Immunovant Inc Stock, XNAS:IMVT

320 West 37th Street, 6th floor, New York, New York 10018

United States of America

Phone: +1.917.580.3099

Number of Employees: 207

http://www.immunovant.com

Description

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in New York, NY.